Reiteration

Bank of America and other analysts are bullish on this software company. Yet short sellers have been betting heavily against the stock. Its share price has been flat in the past few weeks. A meeting with the chief financial officer and other executives at Nutanix Inc (NASDAQ: NTNX) was enough to...

Walt Disney Co (NYSE: DIS)'s move to control its own streaming platform isn't appreciated by many investors given the stock's recent weakness. But why investors are concerned is "beyond us," says Wells Fargo's Marci Ryvicker. Disney's story is "still so misunderstood" as there are many positive...

Following some recent developments at Meritor Inc (NYSE: MTOR), sell-side analysts sounded upbeat on the prospects of the company. While KeyBanc Capital Markets said management could raise the 2019 earnings per share target before the year-end, Longbow Research commended the company for making...

A revision to Buffalo Wild Wings (NASDAQ: BWLD)'s financial model is necessary to reflect promotional changes, the impact of hurricanes Harvey and Irma, and chicken wing prices, analysts at Canaccord Genuity commented in a research report. The firm's Lynne Collier maintains a Hold rating on...

The latest back-to-school data is echoing the sentiment that has been well covered in the sportswear world over the past year; adidas AG (ADR) (OTC: ADDYY) is up and Nike Inc (NYSE: NKE) is down. Fresh off overtaking the Jordan brand as the No. 2 footwear brand in the U.S., Adidas increased sales...

Susquehanna just released its quarterly report on the semiconductor industry, and the latest numbers indicate Advanced Micro Devices, Inc. (NASDAQ: AMD) and Marvell Technology Group Ltd (NASDAQ: MRVL) have been the two big winners of the past quarter. Susquehanna’s PC-SIGnals report analyzes...

Citigroup in a note released Monday, delved into the roadmap for Mirati Therapeutics, Inc. (NASDAQ: MRTX). The firm feels the response for its targeted agent sitravatinib in CBL-mutated non-small cell lung cancer patients puts the company back on targeted therapy map. CBL is a ubiquitin E3 ligase...

Previewing Alcoa Corp (NYSE: AA)'s fiscal year third-quarter results, Morgan Stanley said it expects a beat from the company. As such, the firm has an Overweight rating on the shares of Alcoa and a $47 price target. The company is scheduled to report its third-quarter results after the market...

After a tough start to 2017 for Michael Kors Holdings Ltd (NYSE: KORS) and the rest of the U.S. retail sector, retail stocks have been on the comeback trail in recent weeks. But even with Michael Kors shares up more than 33 percent in the past three months, Oppenheimer analyst Anna Andreeva said...

The hot-and-happening tech sector is going from strength to strength, and the semiconductor sector, which is a major sub-sector within the tech sector, has also performed exceptionally well in recent times. Following its recent checks and distribution survey work, Morgan Stanley discussed in a...

Bank of America's Wamsi Mohan met with some of Nutanix Inc (NASDAQ: NTNX)'s most senior executives, including chief financial officer, Duston Williams, and head of investor relations, Tonya Chin. The main takeaway from the investor meeting was that the company's long-term opportunity remains...

Nike Inc (NYSE: NKE) investors’ patience for a turnaround may be starting to wane. “Patience is wearing thin and panic may be setting in,” said Canaccord Genuity analyst Camilo Lyon as he lowered fiscal year 2018 estimates from $2.34 to $2.32. Since 2015's all-time highs, shares...

After touring the new Tesla Inc (NASDAQ: TSLA) gigafactory in Reno, Baird analyst Ben Kallo is as bullish as ever on Tesla's stock. In a new note Monday, Kallo described ramping production that he believes will lead to capacity expansion and falling costs in the years ahead. Kallo last visited...

Analysts at Bank of America turned incrementally bullish on NVIDIA Corporation (NASDAQ: NVDA) amid multiple notable catalysts that will continue playing out. The firm's Vivek Arya maintains a Buy rating on Nvidia's stock with a price target boosted from $185 to $210. Cloud Capex Surge...

Amid “overstated” legal issues and in the aftermath of natural disaster, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) may profit from a positive catalyst this week, according to H.C. Wainwright & Co. Analyst Raghuram Selvaraju reiterated a Neutral rating on the stock with a $17...